Comprehensive Characterization of Relationship between Higher-Order Structure and FcRn Binding Affinity of Stress-Exposed Monoclonal Antibodies

Pharmaceutical Research

Volumn 33, Issue 4, 2016, Pages 994-1002

  Tsuchida, Daisuke ^a,b   Yamazaki, Katsuyoshi ^a   Akashi, Satoko ^b  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

FcRn; HDX MS; higher order structure; monoclonal antibody

Indexed keywords

FC RECEPTOR; MONOCLONAL ANTIBODY; FC RECEPTOR, NEONATAL; HLA ANTIGEN CLASS 1; IMMUNOGLOBULIN G;

ARTICLE; BINDING AFFINITY; CONFORMATION; CONFORMATIONAL TRANSITION; DEUTERIUM HYDROGEN EXCHANGE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG PURITY; DRUG STRUCTURE; IRRADIATION; MASS SPECTROMETRY; OXIDATION; PRIORITY JOURNAL; STRESS; THERMOSTABILITY; CHEMISTRY; HEAT; IMMUNOLOGY; OXIDATION REDUCTION REACTION; PHOTOLYSIS; PROTEIN CONFORMATION; PROTEIN STABILITY;

ANTIBODIES, MONOCLONAL; HISTOCOMPATIBILITY ANTIGENS CLASS I; HOT TEMPERATURE; IMMUNOGLOBULIN G; OXIDATION-REDUCTION; PHOTOLYSIS; PROTEIN CONFORMATION; PROTEIN STABILITY; RECEPTORS, FC;

EID: 84960376112     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-015-1845-5     Document Type: Article

References (35)

1. Wang W, Singh S, Zeng DL, King K, Nema S. Antibody structure, instability, and formulation. J Pharm Sci. 2007;96(1):1-26.
2. Beck A, Wurch T, Bailly C, Corvaia N. Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol. 2010;10(5):345-52.
3. Ecker DM, Jones SD, Levine HL. The therapeutic monoclonal antibody market. mAbs. 2015;7(1):9-14.
4. Cohen-Solal JF, Cassard L, Fridman W-H, Sautès-Fridman C. Fc γ receptors. Immunol Lett. 2004;92(3):199-205.
5. Raghavan M, Bjorkman PJ. Fc receptors and their interactions with immunoglobulins. Annu Rev Cell Dev Biol. 1996;12:181-220.
6. Ravetch JV, Bolland S. IgG Fc receptors. Annu Rev Immunol. 2001;19:275-90.
7. Albanesi M, Daëron M. The interactions of therapeutic antibodies with Fc receptors. Immunol Lett. 2012;143(1):20-7.
8. Phuan P-W, Zhang H, Asavapanumas N, Leviten M, Rosenthal A, Tradtrantip L, et al. C1q-targeted monoclonal antibody prevents complement-dependent cytotoxicity and neuropathology in in vitro and mouse models of neuromyelitis optica. Acta Neuropathol. 2013;125(6):829-40.
9. Zhang A, Hu P, MacGregor P, Xue Y, Fan H, Suchecki P, et al. Understanding the conformational impact of chemical modifications on monoclonal antibodies with diverse sequence variation using hydrogen/deuterium exchange mass spectrometry and structural modeling. Anal Chem. 2014;86(7):3468-75.
10. Bertolotti-Ciarlet A, Wang W, Lownes R, Pristatsky P, Fang Y, McKelvey T, et al. Impact of methionine oxidation on the binding of human IgG1 to Fc Rn and Fcγ receptors. Mol Immunol. 2009;46:1878-82.
11. Wang W, Vlasak J, Li Y, Pristatsky P, Fang Y, Pittman T, et al. Impact of methionine oxidation in human IgG1 Fc on serum half-life of monoclonal antibodies. Mol Immunol. 2011;48:860-6.
12. Gao X, Ji JA, Veeravalli K, Wang YJ, Zhang T, Mcgreevy W, et al. Effect of individual Fc methionine oxidation on FcRn binding: Met252 oxidation impairs FcRn binding more profoundly than Met428 oxidation. J Pharm Sci. 2015;104(2):368-77.
13. Stracke J, Emrich T, Rueger P, Schlothauer T, Kling L, Knaupp A, et al. A novel approach to investigate the effect of methionine oxidation on pharmacokinetic properties of therapeutic antibodies. mAbs. 2014;6(5):1229-42.
14. FDA. Guidance for industry quality considerations in demonstrating biosimilarity of a therapeutic protein product to a reference product. 2015.
15. Houde D, Arndt J, Domeier W, Berkowitz S, Engen JR. Characterization of IgG1 conformation and conformational dynamics by hydrogen/deuterium exchange mass spectrometry. Anal Chem. 2009;81:2644-51.
16. Zhang Q, Willison LN, Tripathi P, Sathe SK, Roux KH, Emmett MR, et al. Epitope mapping of a 95 kDa antigen in complex with antibody by solution-phase amide backbone hydrogen/deuterium exchange monitored by Fourier transform ion cyclotron resonance mass spectrometry. Anal Chem. 2011;83:7129-36.
17. Obungu VH, Gelfanova V, Rathnachalam R, Bailey A, Sloan-Lancaster J, Huang L. Determination of the mechanism of action of anti-FasL antibody by epitope mapping and homology modeling. Biochemistry. 2009;48:7251-60.
18. Zhang A, Singh SK, Shirts MR, Kumar S, Fernandez EJ. Distinct aggregation mechanisms of monoclonal antibody under thermal and freeze-thaw stresses revealed by hydrogen exchange. Pharm Res. 2012;29:236-50.
19. Iacob RE, Bou-Assaf GM, Makowski L, Engen JR, Berkowitz SA, Houde D. Investigating monoclonal antibody aggregation using a combination of H/DX-MS and other biophysical measurement. J Pharm Sci. 2013;102:4315-29.
20. Tsuchida D, Yamazaki K, Akashi S. Characterization of stress-exposed granulocyte colony stimulating factor using ELISA and hydrogen/deuterium exchange mass spectrometry. J Am Soc Mass Spectrom. 2014;25(10):1747-54.
21. ICH. ICH harmonised tripartite guideline, stability testing: photostability testing of new drug substances and products. 1996.
22. Glasoe PK, Long FA. Use of glass electrodes to measure acidities in deuterium oxide. J Phys Chem. 1960;64:188-9.
23. Connelly GP, Bai Y, Jeng MF, Englander SW. Isotope effects in peptide group hydrogen exchange. Proteins. 1993;17:87-92.
24. Walters BT, Ricciuti A, Mayne L, Englander SW. Minimizing back exchange in the hydrogen exchange-mass spectrometry experiment. J Am Soc Mass Spectrom. 2012;23:2132-9.
25. Wales TE, Engen JR. Hydrogen exchange mass spectrometry for the analysis of protein dynamics. Mass Spectrom Rev. 2006;25:158-70.
26. Cordoba AJ, Shyong B-J, Breen D, Harris RJ. Non-enzymatic hinge region fragmentation of antibodies in solution. J Chromatogr B. 2005;818:115-21.
27. Sharov VS, Ferrington DA, Squier TC, Schöneich C. Diastereoselective reduction of protein-bound methionine sulfoxide by methionine sulfoxide reductase. FEBS Lett. 1999;455(3):247-50.
28. Khor HK, Jacoby ME, Squier TC, Chu GC, Chelius D. Identification of methionine sulfoxide diastereomers in immunoglobulin gamma antibodies using methionine sulfoxide reductase enzymes. mAbs. 2010;2(3):299-308.
29. Costantino HR, Andya JD, Shire SJ, Hsu CC. Fourier-transform infrared spectroscopic analysis of the secondary structure of recombinant humanized immunoglobulin G. J Pharm Sci. 1997;3:121-8.
30. Maury M, Murphy K, Kumar S, Mauerer A, Lee G. Spray-drying of proteins: effects of sorbitol and trehalose on aggregation and FT-IR amide I spectrum of an immunogloblin G. Eur J Pharm Biopharm. 2005;59:251-61.
31. Strickland EH. Aromatic contributions to circular dichroism spectra of proteins. CRC Crit Rev Biochem. 1974;2(1):113-75.
32. Bosch JP, Geronemus R, Glabman S, Lysaght M, Kahn T, von Albertini B. High flux hemofiltration. Artif Organs. 1978;2(4):339-42.
33. Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J, et al. High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR. J Biol Chem. 2001;276(9):6591-604.
34. Vermeer AWP, Norde W. The thermal stability of immunoglobulin: unfolding and aggregation of a multi-domain protein. Biophys J. 2000;78(1):394-404.
35. Garber E, Demarest SJ. A broad range of Fab stabilities within a host of therapeutic IgGs. Biochem Biophys Res Commun. 2007;355(3):751-7.